|
Q4 FY2026
As of Jun 30, 2026
|
Q3 FY2026
As of Mar 31, 2026
|
Q2 FY2026
As of Dec 31, 2025
|
Q1 FY2026
As of Sep 30, 2025
|
Q4 FY2025
As of Jun 30, 2025
|
Q3 FY2025
As of Mar 31, 2025
|
Q2 FY2025
As of Dec 31, 2024
|
Q1 FY2025
As of Sep 30, 2024
|
Q4 FY2024
As of Jun 30, 2024
|
Q3 FY2024
As of Mar 31, 2024
|
Q2 FY2024
As of Dec 31, 2023
|
Q1 FY2024
As of Sep 30, 2023
|
Q4 FY2023
As of Jun 30, 2023
|
Q3 FY2023
As of Mar 31, 2023
|
Q2 FY2023
As of Dec 31, 2022
|
Q1 FY2023
As of Sep 30, 2022
|
Q4 FY2022
As of Jun 30, 2022
|
Q3 FY2022
As of Mar 31, 2022
|
Q2 FY2022
As of Dec 31, 2021
|
Q1 FY2022
As of Sep 30, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current assets | ||||||||||||||||||||
| Cash | ||||||||||||||||||||
| Cash | ||||||||||||||||||||
| Accounts receivable, net | ||||||||||||||||||||
| Inventory, net | ||||||||||||||||||||
| Prepaid expenses and other receivables | ||||||||||||||||||||
| Due from Bloomios | ||||||||||||||||||||
| Due from VitaMedica transition | ||||||||||||||||||||
| Prepaid expenses and other assets | ||||||||||||||||||||
| Current assets of discontinued operations | ||||||||||||||||||||
| Assets available for sale - Interactive offers current | ||||||||||||||||||||
| Assets available for sale - Building | ||||||||||||||||||||
| Assets available for sale - VitaMedica current | ||||||||||||||||||||
| Assets available for sale - E-core current | ||||||||||||||||||||
| Current digital assets at fair value | ||||||||||||||||||||
| Purchase price receivable - VitaMedica | ||||||||||||||||||||
| Purchase price receivable - E-core | ||||||||||||||||||||
| Total current assets | ||||||||||||||||||||
| Property and equipment, net | ||||||||||||||||||||
| Intangible assets, net | ||||||||||||||||||||
| Goodwill | ||||||||||||||||||||
| Deferred tax asset | ||||||||||||||||||||
| Investment in digital company | ||||||||||||||||||||
| Digital assets at fair value, net of current | ||||||||||||||||||||
| Other assets | ||||||||||||||||||||
| Assets held for sale | ||||||||||||||||||||
| Discontinued assets available for sale - Interactive offers | ||||||||||||||||||||
| Discontinued assets available for sale - VitaMedica | ||||||||||||||||||||
| Discontinued assets available for sale - E-core | ||||||||||||||||||||
| Right-of-use asset, net | ||||||||||||||||||||
| Total other assets | ||||||||||||||||||||
| Total noncurrent assets | ||||||||||||||||||||
| Total assets | ||||||||||||||||||||
| Current liabilities | ||||||||||||||||||||
| Accounts payable | ||||||||||||||||||||
| Accrued compensation | ||||||||||||||||||||
| Deferred revenue | ||||||||||||||||||||
| Accrued compensation | ||||||||||||||||||||
| Deferred revenue | ||||||||||||||||||||
| Accrued interest expenses | ||||||||||||||||||||
| Accrued interest | ||||||||||||||||||||
| Acquisition payable | ||||||||||||||||||||
| Related party advances, net | ||||||||||||||||||||
| Outstanding balance of notes payable | ||||||||||||||||||||
| Current portion of acquisition note payable - E-core | ||||||||||||||||||||
| Line of Credit | ||||||||||||||||||||
| Current portion of convertible notes payable | ||||||||||||||||||||
| Current portion of related party note payable | ||||||||||||||||||||
| Short-term treasury debt | ||||||||||||||||||||
| Current portion of Cygnet subsidiary notes payable | ||||||||||||||||||||
| Discontinued liabilities - Interactive offers | ||||||||||||||||||||
| Discontinued liabilities - VitaMedica | ||||||||||||||||||||
| Discontinued liabilities - E-core | ||||||||||||||||||||
| Note payable on building for sale | ||||||||||||||||||||
| Current portion of operating lease payable | ||||||||||||||||||||
| Current liabilities of discontinued operations | ||||||||||||||||||||
| Total current liabilities | ||||||||||||||||||||
| Operating lease payable, net of current portion | ||||||||||||||||||||
| Related party note payable | ||||||||||||||||||||
| Note payable | ||||||||||||||||||||
| Notes payable - Cygnet subsidiary | ||||||||||||||||||||
| Convertible notes payable | ||||||||||||||||||||
| Acquisition notes payable, net of current | ||||||||||||||||||||
| Notes payable, net of current portion | ||||||||||||||||||||
| Acquisition note payable - E-core | ||||||||||||||||||||
| Total long-term liabilities | ||||||||||||||||||||
| Stockholders' equity | ||||||||||||||||||||
| Preferred stock, $0.00001 par value, 10,000,000 shares authorized, and 150,000 shares issued and outstanding | ||||||||||||||||||||
| Common stock, $0.001 par value, 5,000,000 shares authorized, and 1,010,843 and 1,045,429 shares issued and outstanding, respectively | ||||||||||||||||||||
| Common stock, $0.00001 par value, 1,000,000,000 shares authorized, 78,702,358 and 38,270,571 shares issued and outstanding, as of June 30, 2026 and June 30, 2025, respectively | ||||||||||||||||||||
| Treasury stock, 416,226 and 0, as of December 31, 2025 and June 30, 2025, respectively | ||||||||||||||||||||
| Additional paid in capital | ||||||||||||||||||||
| Accumulated deficit | ||||||||||||||||||||
| Total stockholders' equity attributable to Upexi, Inc. | ||||||||||||||||||||
| Total stockholders' equity | ||||||||||||||||||||
| Total stockholders' equity | ||||||||||||||||||||
| Total liabilities and stockholders' equity | ||||||||||||||||||||
Loading...
